Skip to content
Riskpilot
← Back to search
Sign in
Get full access
RxElites AB
AB
Active
Org 5595217034
Krokåkersgatan 34, 234 38
Lomma
Retail sale of pharmaceutical products
·
NACE 4773
Est. 2025 · 1 year old
1-4 employees
Monitor
Share
Sweden
/
Companies
/
Retail sale of pharmaceutical products
/
RxElites AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
1M
2025
EBITDA
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2025
Income statement
SEK thousands
Item
2025
Revenue
840
Staff expenses
−317
EBITDA
461
Depreciation & amort.
—
EBIT
461
Net financials
−0
Profit before tax
461
Tax
−95
Net profit
366
Balance sheet
SEK thousands
Item
2025
Total assets
565
Equity
391
Long-term debt
3
Short-term debt
171
Total debt
175
Financial ratios
5-year trend
EBITDA margin
54.9%
This company
15.8%
Market median
+247% vs market
2025
2025
Equity ratio
69.1%
This company
38.2%
Market median
+81% vs market
2025
2025
Return on equity
93.6%
This company
18.4%
Market median
+409% vs market
2025
2025
Net profit margin
43.5%
This company
8.1%
Market median
+437% vs market
2025
2025
Asset turnover
1.49×
This company
1.12×
Market median
+33% vs market
2025
2025
Debt / equity
0.45×
This company
0.62×
Market median
+27% vs market
2025
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-03-03 – 2025-12-31
View
PDF
More on RxElites AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
